{"id":758546,"date":"2023-05-12T16:03:08","date_gmt":"2023-05-12T20:03:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/"},"modified":"2023-05-12T16:03:08","modified_gmt":"2023-05-12T20:03:08","slug":"outcome-of-innate-pharmas-2023-annual-general-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/","title":{"rendered":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting"},"content":{"rendered":"

<\/p>\n

Outcome of Innate Pharma\u2019s 2023 Annual General Meeting<\/b><\/p>\n

MARSEILLE, France–(BUSINESS WIRE<\/a>)–
\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate<\/b>\u201d or the \u201cCompany<\/b>\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 12, 2023, in Marseille. All resolutions were voted.<\/p>\n

\nA total of 112 votes were cast out of a total of 36,142,912 shares giving right to 36,618,940 voting rights, representing a quorum of 44.928%.<\/p>\n

\nDuring the meeting, all seven members of the Supervisory Board who were up for election were re-elected.<\/p>\n

\nThe resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2023<\/a> section of the Company\u2019s website.<\/p>\n

About Innate Pharma<\/b><\/p>\n

\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET\u00ae<\/sup> (A<\/b>ntibody-based NK<\/b> cell E<\/b>ngager T<\/b>herapeutics) proprietary platform.<\/p>\n

\nInnate\u2019s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET\u00ae<\/sup> multi-specific NK cell engagers to address multiple tumor types.<\/p>\n

\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.<\/p>\n

\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n

\nLearn more about Innate Pharma at www.innate-pharma.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

Information about Innate Pharma shares<\/b><\/p>\n\n\n
\n

ISIN code
\n<\/b>
Ticker code
\n<\/b>
LEI<\/b><\/p>\n<\/td>\n

\n

\nFR0010331421<\/p>\n

\nEuronext: IPH Nasdaq: IPHA<\/p>\n

\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n

Disclaimer on forward-looking information and risk factors<\/b><\/p>\n

\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.<\/p>\n

\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230512005280\/en\/<\/a><\/span><\/p>\n

Investors <\/span><\/b><\/p>\n

Innate Pharma
\n<\/b>
Henry Wheeler
\n
Tel.: +33 (0)4 84 90 32 88
\n
Henry.wheeler@innate-pharma.fr<\/a><\/p>\n

Media Relations<\/span><\/b><\/p>\n

NewCap
\n<\/b>
Arthur Rouill\u00e9
\n
Tel.: +33 (0)1 44 71 00 15
\n
innate@newcap.eu<\/a><\/p>\n

KEYWORDS:<\/b> France Europe<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Outcome of Innate Pharma\u2019s 2023 Annual General Meeting MARSEILLE, France–(BUSINESS WIRE)– Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 12, 2023, in Marseille. All resolutions were voted. A total of 112 votes were cast out of a total of 36,142,912 shares giving right to 36,618,940 voting rights, representing a quorum of 44.928%. During the meeting, all seven members of the Supervisory Board who were up for election were re-elected. The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2023 section … <\/p>\n

Continue reading “Outcome of Innate Pharma\u2019s 2023 Annual General Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758546","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOutcome of Innate Pharma\u2019s 2023 Annual General Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting MARSEILLE, France–(BUSINESS WIRE)– Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 12, 2023, in Marseille. All resolutions were voted. A total of 112 votes were cast out of a total of 36,142,912 shares giving right to 36,618,940 voting rights, representing a quorum of 44.928%. During the meeting, all seven members of the Supervisory Board who were up for election were re-elected. The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2023 section … Continue reading "Outcome of Innate Pharma\u2019s 2023 Annual General Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T20:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting\",\"datePublished\":\"2023-05-12T20:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/\"},\"wordCount\":633,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/\",\"name\":\"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-12T20:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outcome-of-innate-pharmas-2023-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting - Market Newsdesk","og_description":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting MARSEILLE, France–(BUSINESS WIRE)– Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 12, 2023, in Marseille. All resolutions were voted. A total of 112 votes were cast out of a total of 36,142,912 shares giving right to 36,618,940 voting rights, representing a quorum of 44.928%. During the meeting, all seven members of the Supervisory Board who were up for election were re-elected. The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2023 section … Continue reading \"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-12T20:03:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting","datePublished":"2023-05-12T20:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/"},"wordCount":633,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/","name":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-12T20:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230512005280r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outcome-of-innate-pharmas-2023-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outcome of Innate Pharma\u2019s 2023 Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758546"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758546\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}